Search Results for “” – Page 6 – OSLM

OSLM

Outcome Studies
in Laboratory Medicine

guest

👤

Learn more about this platform

Categories:Economics Model

111 Publications found

Estimated Cost-effectiveness of Newborn Screening for Congenital Cytomegalovirus Infection in China Using a Markov Model.

b

JAMA network open

December 1, 2020

p Newborn Screening

c Economics Highlighted Model
The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism.

b

International journal of neonatal screening

November 20, 2020

p Newborn Screening

c Economics Model
Cost-effectiveness of adoption strategies for point of care HIV viral load monitoring in South Africa.

b

EClinicalMedicine

November 1, 2020

p HIV POCT

c Economics Model
The potential for quality assurance systems to save costs and lives: the case of early infant diagnosis of HIV.

b

Tropical medicine & international health : TM & IH

October 1, 2020

p HIV POCT

c Economics Model
The cost-effectiveness of conducting three versus two reverse transcription-polymerase chain reaction tests for diagnosing and discharging people with COVID-19: evidence from the epidemic in Wuhan, China.

b

BMJ global health

July 1, 2020

p COVID-19

c Economics Model
Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States.

b

JAMA network open

July 1, 2020

p COVID-19

c Economics Model
Strengthening Existing Laboratory-Based Systems vs. Investing in Point-of-Care Assays for Early Infant Diagnosis of HIV: A Model-Based Cost-Effectiveness Analysis.

b

Journal of acquired immune deficiency syndromes (1999)

July 1, 2020

p HIV POCT

c Economics Model
A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.

b

Acta clinica Belgica

June 1, 2020

p Newborn Screening

c Economics Model
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

b

Gut

April 1, 2020

p Inflammatory Bowel Disease

c Clinical outcomes Economics Model
Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort.

b

Inflammatory bowel diseases

January 1, 2020

p Therapeutic drug monitoring

c Economics Model